GlassScriptPhysician profile
David G Booth
NPI 1154397404
$662.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $123.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $218.19 | 2019-2020 | |
| Novo Nordisk INC | $92.91 | 2019-2020 | |
| Amgen INC. | $75.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.63 | 2019-2020 | |
| Astellas Pharma US INC | $22.17 | 2019 | |
| Radius Health, INC. | $21.80 | 2019 | |
| Medtronic Vascular, INC. | $15.89 | 2019 | |
| Mylan Specialty L.P. | $15.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.63 | 2019 | |
| Merck Sharp & Dohme LLC | $12.39 | 2019 | |
| Lilly USA, LLC | $12.17 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.